Zobrazeno 1 - 10
of 50
pro vyhledávání: '"S Thoelen"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S Thoelen, Geert Leroux-Roels, Guido Moens, Martine Wettendorff, J Dewijngaert, P Jacques, Isabelle Desombere
Publikováno v:
Vaccine. 20:3644-3649
Approximately 5% of vaccinees display an inadequate response after the administration of the standard three dose hepatitis B vaccine. A new hepatitis B vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3'-deacylated monophosphoryl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73d3a7cfeb44466746033a8e3d7c3cbc
https://doi.org/10.1016/s0264-410x(02)00397-3
https://doi.org/10.1016/s0264-410x(02)00397-3
Autor:
Gerhard Wiedermann, N. Garcon, F. Ambrosch, C. Thiriart, Moncef Mohamed SmithKline Beecham Bio. s.a Slaoui, Isabelle Desombere, Geert Leroux-Roels, M. Kundi, S Thoelen
Publikováno v:
Vaccine. 18:2095-2101
Although more than 95% of the vaccinated population responds to the currently licensed vaccines against hepatitis B, some groups were found to be low responders. Lipid A as adjuvant, through its ability to activate macrophages, might improve humoral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb76a66b7a9e54b1e9f7b20d828e9dbe
https://doi.org/10.1016/s0264-410x(99)00566-6
https://doi.org/10.1016/s0264-410x(99)00566-6
Publikováno v:
Journal of Travel Medicine. 3:83-90
Background: In recent years, several hepatitis A vaccines have been developed. We wished to evaluate the safety, reactogenicity, and immunogenicity of an inactivated hepatitis A vaccine, containing 1440 EI.U., and to monitor the kinetics of the antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7baf510f3419984d0646748ecf4e060
https://doi.org/10.1111/j.1708-8305.1996.tb00711.x
https://doi.org/10.1111/j.1708-8305.1996.tb00711.x
Publikováno v:
Vaccine. 19(9-10)
Twinrix™ (SmithKline Beecham Biologicals) is a combined hepatitis A and B vaccine licensed with a three-dose schedule. A two-dose combined hepatitis A and B vaccine would facilitate immunisation programs. In this prospective study, 100 healthy adul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27612537586853e3856632c35ba2e112
https://pubmed.ncbi.nlm.nih.gov/11137246
https://pubmed.ncbi.nlm.nih.gov/11137246
Autor:
S, Thoelen
Publikováno v:
Acta gastro-enterologica Belgica. 63(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc60de36aa36b0700ed170782705346d
https://pubmed.ncbi.nlm.nih.gov/10925458
https://pubmed.ncbi.nlm.nih.gov/10925458
Autor:
A Leentvaar-Kuypers, V Bakasenas, M Bruguera, P. Van Damme, S. Thoelen, Geert Leroux-Roels, Assad Safary, P. C. Frei
Publikováno v:
Vaccine
Hepatitis A and B infections are prevalent world-wide and are a significant cause of morbidity and mortality. A vaccine providing dual protection against hepatitis A and B is now available (Twinrix, SmithKline Beecham Biologicals). Six pivotal vaccin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d756568656bf4fd5c2defb5627a19947
https://pubmed.ncbi.nlm.nih.gov/10194819
https://pubmed.ncbi.nlm.nih.gov/10194819
Publikováno v:
Vaccine
The aim of this study was to evaluate the persistence of antibodies 7 years after hepatitis B booster administration in healthy adult volunteers who were vaccinated in 1987. In October 1986, 188 seronegative, healthy adult volunteers (117 men and 71
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e07940f22cd4454f2002e2e5e62143
https://pubmed.ncbi.nlm.nih.gov/9796046
https://pubmed.ncbi.nlm.nih.gov/9796046
Autor:
Isabelle Desombere, Moncef Mohamed Slaoui, S. Thoelen, Pierre Vandepapelière, C. Matheï, Assad Safary, André Meheus, Geert Leroux-Roels, P. Van Damme
Publikováno v:
Vaccine
A formulation of recombinant hepatitis B surface antigen (HBsAg) combined with a novel adjuvant system, SBAS4—a combination of aluminium salt and monophosphoryl lipid A (MPL), was assessed in 27 healthy adult volunteers with a commercial vaccine (E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05386bcc5ab0b65bd91824ca6a0a4f49
https://hdl.handle.net/10067/208040151162165141
https://hdl.handle.net/10067/208040151162165141
Publikováno v:
Journal of medical virology
In comparison with the classical immunisation schedules (0-1-6 or 0-1-12 months) for hepatitis A, a 0- and 12- or a 0- and 6-month schedule would have important advantages by reducing the number of injections and discomfort and increasing scheduling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a15025363780d5e7e8caee6a891c154
https://hdl.handle.net/10067/86060151162165141
https://hdl.handle.net/10067/86060151162165141